Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Studying Biomarkers in Samples From Younger Patients With Kidney Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01642095
Recruitment Status : Withdrawn
First Posted : July 17, 2012
Last Update Posted : August 7, 2018
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group

Brief Summary:
This laboratory study is looking into biomarkers in samples from younger patients with kidney cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.

Condition or disease Intervention/treatment
Childhood Kidney Neoplasm Clear Cell Renal Cell Carcinoma Congenital Mesoblastic Nephroma Rhabdoid Tumor of the Kidney Other: Laboratory Biomarker Analysis

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine whether focal adhesion kinase (FAK) is expressed and if FAK is phosphorylated in pediatric renal tumors.

OUTLINE:

Archived tumor tissue samples are analyzed for FAK expression by immunohistochemistry (IHC). IHC staining is compared in normal renal tissue, Wilms tumor (routine and anaplastic), malignant rhabdoid tumor of the kidney, clear cell sarcoma of the kidney, and mesoblastic nephroma.


Layout table for study information
Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Focal Adhesion Kinase Expression in Pediatric Renal Tumors
Actual Study Start Date : August 22, 2012
Actual Primary Completion Date : September 1, 2012


Group/Cohort Intervention/treatment
Basic science (FAK expression)
Archived tumor tissue samples are analyzed for FAK expression by IHC. IHC staining is compared in normal renal tissue, Wilms tumor (routine and anaplastic), malignant rhabdoid tumor of the kidney, clear cell sarcoma of the kidney, and mesoblastic nephroma.
Other: Laboratory Biomarker Analysis
Correlative studies




Primary Outcome Measures :
  1. FAK expression in pediatric renal tumors [ Time Frame: Baseline ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Criteria

Inclusion Criteria:

  • Formalin-fixed, paraffin-embedded tissue samples from patients diagnosed with the following renal tumors:

    • Anaplastic Wilms tumor
    • Malignant rhabdoid tumor of the kidney
    • Clear cell sarcoma of the kidney
    • Mesoblastic nephroma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01642095


Locations
Layout table for location information
United States, Pennsylvania
Childrens Oncology Group
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Elizabeth Beierle Children's Oncology Group

Layout table for additonal information
Responsible Party: Children's Oncology Group
ClinicalTrials.gov Identifier: NCT01642095     History of Changes
Other Study ID Numbers: AREN12B8
NCI-2012-01987 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
CDR0000736805
AREN12B8
COG-AREN12B8
AREN12B8 ( Other Identifier: Childrens Oncology Group )
AREN12B8 ( Other Identifier: CTEP )
First Posted: July 17, 2012    Key Record Dates
Last Update Posted: August 7, 2018
Last Verified: October 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Renal Cell
Rhabdoid Tumor
Kidney Neoplasms
Nephroma, Mesoblastic
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Neoplasms, Complex and Mixed